The Rapid Rise of Online Prescription Drug Sales in China
China’s pharmaceutical e-commerce market has experienced explosive growth in recent years, particularly in the realm of prescription medications. Driven by policy changes supporting online drug purchases, prescription drugs have captured an increasingly significant share of the retail market outside traditional hospitals. According to authoritative data from sources like米内网 and中康CMH, online sales of prescription drugs reached an estimated 35-40 billion RMB in 2024, with prescription products outperforming over-the-counter medications for five consecutive years in online market share.
This remarkable growth trajectory shows no signs of slowing, as pharmaceutical e-commerce continues its strong expansion. At the heart of this phenomenon lies the electronic prescription system, which has enabled the seamless online sale of prescription medications. The convenience for consumers has been undeniable, but this convenience comes with complex implications for healthcare quality and safety.
The Engine Behind the Growth: Electronic Prescriptions
The massive scale of online prescription drug sales depends entirely on the availability of electronic prescriptions from internet hospitals. These digital authorizations have become surprisingly inexpensive, with current market prices averaging just 0.4-0.6 RMB per prescription. This incredibly low cost has enabled the industry to process staggering volumes – leading platforms now issue over 20 million prescriptions annually, with nationwide electronic prescriptions reaching hundreds of millions.
The Electronic Prescription Assembly Line: How 4-Cent Prescriptions Work
Behind these remarkably inexpensive electronic prescriptions lies a sophisticated and highly efficient supply chain. Major pharmaceutical e-commerce platforms (including Meituan, Ele.me, and Ali Health) connect consumers with medication needs to external suppliers who provide prescription services. These suppliers, operating with internet hospital qualifications, in turn recruit physicians – primarily part-time – to provide the actual prescription services.
The system operates similarly to ride-hailing platforms like DiDi, where doctors flexibly accept prescription requests as they become available. Based on actual prescriptions issued, e-commerce platforms pay external suppliers 0.4-0.8 RMB per prescription. These supplier companies then pay doctors between 0.2-0.4 RMB per prescription, with specific compensation determined by metrics including prescription volume, online availability, and crucially, the 10-second prescription approval rate.
The Doctor’s Role in the Prescription Assembly Line
Physicians participating in these systems describe a process heavily dominated by AI assistance. One doctor who worked with a leading internet hospital revealed receiving just 0.4 RMB per prescription issued. The time pressure is intense: while proper electronic prescription review should take at least one minute, most platforms expect doctors to complete the process within 10 seconds. This leaves insufficient time for proper risk assessment, forcing physicians to rely primarily on AI risk alerts before quickly clicking confirmation.
In this environment, AI has effectively become the invisible prescriber, raising serious questions about medication safety and professional oversight. The pressure to maintain high volume and speed creates conditions where patient-specific factors like allergy history or potential adverse reactions may receive inadequate attention, with systems often defaulting to patient self-reporting through checkboxes.
Regulatory Evolution: From Absolute Ban to Controlled Opening
The current operation of electronic prescriptions represents the outcome of ongoing negotiation between policy regulation and market demands. Understanding how we arrived at this point requires examining the gradual evolution of China’s approach to online pharmaceutical sales.
In the late 1990s, as internet adoption grew in China, early attempts at online pharmacy faced immediate regulatory barriers. The 1999 ‘Provisional Regulations on the Circulation Management of Prescription and Non-Prescription Drugs’ effectively prohibited online sales of both categories of medication, creating a six-year policy vacuum for pharmaceutical e-commerce.
The first opening emerged in 2005 with the ‘Provisional Regulations on Internet Drug Transaction Service Approval,’ which created A/B/C classification for pharmaceutical e-commerce licenses. Chain pharmacies holding C certificates gained permission to sell non-prescription drugs online, though prescription medications remained excluded. This narrow opening led to the issuance of the first pharmaceutical B2C license in 2006, but regulatory caution persisted. In 2016, concerned about unclear accountability and违规 sales of prescription drugs, the CFDA suspended third-party platform pilots, tightening policies once again.
The Policy Turning Point
The significant breakthrough came in 2018 when the General Office of the State Council issued the ‘Opinions on Promoting Internet Plus Healthcare Development.’ This document first granted legal status to electronic prescriptions, allowing online issuance for common and chronic conditions, with pharmacist review and third-party delivery permission. This framework represented the starting point for electronic prescription authentication, recognizing their legal validity while proposing prescription information sharing between medical institutions and retail pharmacies.
An even greater breakthrough arrived in 2021 with the State Council’s ‘Opinions on Serving the Six Stabilities and Six Guarantees to Further Reform Delegating Power, Improving Regulation, and Upgrading Services.’ This policy彻底 lifted restrictions on online prescription drug sales (excluding specially controlled medications), provided electronic prescription sources were authentic and reliable. This ended a twenty-two-year prohibition on online prescription drug sales.
Prescription流转合法化 was only the first step; integrating with医保结算 presented higher barriers due to varying technical standards across regional医保 systems. A key breakthrough came in February 2023 when the National Healthcare Security Administration issued the ‘Notice on Further Including Designated Retail Pharmacies in Outpatient Coordination Management,’ allowing designated pharmacies to provide outpatient coordination services with the same reimbursement terms as primary hospitals.
Balancing Efficiency, Cost and Safety in Online Pharmaceuticals
The current electronic prescription system represents a remarkable achievement in healthcare efficiency and accessibility, but it also raises significant questions about quality and safety. The stark contrast between traditional online consultations (costing数十元) and simple prescription renewals (costing just几毛钱) highlights the tension between healthcare as a professional service and healthcare as a commodified transaction.
Some pharmacies and platforms have developed workarounds that further complicate the safety picture, including manipulating prescription timing to create the appearance of compliance when actually practicing ‘sell first, prescribe later.’ The prohibition on internet diagnosis and treatment for initial consultations is similarly circumvented through these mechanisms. As one interviewed physician noted: ‘As long as the AI risk control doesn’t flag it, doctors won’t scrutinize carefully – they just click confirm.’
The Path Forward: Sustainable Growth with Patient Safety
As policy continues to evolve,医保 systems become more interconnected, and AI and internet hospital technologies mature, the online prescription drug market will undoubtedly continue expanding. The central challenge for regulators and industry participants alike will be balancing efficiency and cost considerations with fundamental obligations to patient safety.
Potential areas for improvement include enhancing AI decision-support systems to better flag potential medication risks, implementing more robust physician verification processes despite time pressures, and developing clearer accountability frameworks when prescriptions originate from complex multi-party systems. Transparency about how these systems operate – both to regulators and to consumers – will be essential for building trust in this rapidly evolving sector.
The electronic prescription revolution has demonstrated the powerful benefits of digital transformation in healthcare, but sustainable growth will require addressing the legitimate concerns about quality and safety that emerge when medical decisions become industrialized processes. Getting this balance right will determine whether China’s pharmaceutical e-commerce market can truly deliver on its promise of accessible, affordable, and safe healthcare for millions of consumers.
– – –
What’s your experience with online pharmacy services? Have you encountered remarkably fast prescription approvals or surprisingly low healthcare costs? Share your perspective on how digital healthcare can balance efficiency with quality and safety considerations.